🇺🇸 UTHR — United Therapeutics Corporation
Salud CompraPrecio actual
608,49 USD
Máx. histórico
608,49
0 días
Split 2:1 del 23/09/2009
Caída desde máximo
En máximo
Rango 52 semanas
432,53 – 614,23
Variación hoy
+1,19%
Cierre anterior
601,32
Rango de hoy
578,28 – 614,23
Volumen hoy
908.530
Peor caída histórica
-93,18%
12/07/2000 → 10/12/2001
Recuperado en 3311 días
Volatilidad anualizada ⓘ
46,95%
- Nombre completo
- United Therapeutics Corporation
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Drug Manufacturers - Specialty & Generic
- Empleados
- 1.400
- PER ⓘ
- 21,57 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 670,93 USD (puede no estar actualizado)
- Primera cotización
- 17/06/1999
- Precio actualizado
- hace 19 horas
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
| Fecha | Ratio |
|---|---|
| 23/09/2009 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 07/03/2017 | 145,34 | 147,09 | 144,15 | 144,99 | -1,45% | 2,02% | 492.900 |
| 06/03/2017 | 146,70 | 148,27 | 144,57 | 147,13 | -1,57% | 2,52% | 529.200 |
| 03/03/2017 | 147,61 | 149,56 | 147,08 | 149,47 | +1,55% | 1,68% | 358.600 |
| 02/03/2017 | 148,40 | 149,64 | 146,60 | 147,19 | -0,57% | 2,05% | 504.500 |
| 01/03/2017 | 150,46 | 152,86 | 147,55 | 148,03 | +0,21% | 3,53% | 1.128.600 |
| 28/02/2017 | 153,58 | 153,58 | 146,65 | 147,72 | -3,14% | 4,51% | 944.800 |
| 27/02/2017 | 146,77 | 152,95 | 146,77 | 152,51 | +3,95% | 4,21% | 872.300 |
| 24/02/2017 | 145,96 | 147,19 | 145,57 | 146,71 | -0,50% | 1,11% | 414.100 |
| 23/02/2017 | 146,17 | 148,54 | 142,00 | 147,44 | +0,31% | 4,47% | 1.092.300 |
| 22/02/2017 | 160,92 | 161,30 | 146,84 | 146,98 | -12,47% | 8,99% | 1.620.800 |
| 21/02/2017 | 169,31 | 169,89 | 165,76 | 167,92 | -0,14% | 2,44% | 600.400 |
| 17/02/2017 | 167,06 | 168,64 | 166,13 | 168,16 | -0,15% | 1,50% | 324.200 |
| 16/02/2017 | 167,57 | 168,82 | 166,50 | 168,42 | +0,32% | 1,38% | 470.800 |
| 15/02/2017 | 165,63 | 168,70 | 164,83 | 167,88 | +1,33% | 2,34% | 328.900 |
| 14/02/2017 | 164,23 | 165,83 | 163,24 | 165,67 | +0,72% | 1,58% | 307.600 |
| 13/02/2017 | 164,05 | 165,31 | 163,50 | 164,48 | +0,24% | 1,10% | 230.400 |
| 10/02/2017 | 165,39 | 165,39 | 163,13 | 164,08 | -0,30% | 1,37% | 235.100 |
| 09/02/2017 | 163,99 | 165,62 | 162,64 | 164,58 | -0,12% | 1,82% | 512.600 |
| 08/02/2017 | 163,05 | 165,98 | 161,37 | 164,78 | +1,20% | 2,83% | 527.000 |
| 07/02/2017 | 165,26 | 165,26 | 162,49 | 162,82 | -0,92% | 1,68% | 384.900 |
| 06/02/2017 | 162,58 | 165,09 | 162,58 | 164,33 | +0,40% | 1,54% | 471.800 |
| 03/02/2017 | 166,43 | 166,68 | 163,29 | 163,68 | -0,86% | 2,04% | 601.000 |
| 02/02/2017 | 163,60 | 166,05 | 160,86 | 165,10 | +0,65% | 3,17% | 547.600 |
| 01/02/2017 | 163,35 | 164,92 | 161,77 | 164,03 | +0,24% | 1,93% | 748.900 |
| 31/01/2017 | 159,13 | 163,99 | 157,58 | 163,63 | +2,48% | 4,03% | 626.900 |
| 30/01/2017 | 161,12 | 161,12 | 157,11 | 159,67 | -1,70% | 2,49% | 520.800 |
| 27/01/2017 | 157,59 | 162,92 | 155,59 | 162,43 | +3,50% | 4,65% | 864.200 |
| 26/01/2017 | 156,13 | 161,47 | 155,18 | 156,94 | -0,22% | 4,03% | 709.100 |
| 25/01/2017 | 157,25 | 158,20 | 155,77 | 157,29 | +0,43% | 1,55% | 657.500 |
| 24/01/2017 | 152,88 | 156,74 | 152,02 | 156,62 | +2,37% | 3,09% | 548.700 |